ASH Clinical News Hematology Pipeline Update: Drug Updates from the | Page 19

Combo of Ixazomib, Lenalidomide, and Dexamethasone
Leads to Longer PFS in Relapsed/Refractory Multiple
Myeloma
The triplet combination of the oral proteasome inhibitor (PI)
ixazomib and the immunomodulatory drugs lenalidomide and
dexamethasone resulted in longer progression-free survival (PFS)
than placebo and lenalidomide/dexamethasone in patients with
relapsed and/or refractory multiple myeloma (MM), according to
interim results from the phase III Tourmaline-MM1 study presented at the 2015 ASH Annual Meeting.
“This all-oral regimen may become one of the new standards of care
in the relapse setting of multiple myeloma. It has a very safe profile,
is a very effective combination, and is simple and convenient,” said
principal investigator, Philippe Moreau, MD, from the University of
Nantes in France.
The current trial was designed based on a previous phase I/II
study in which this three-drug combination resulted in an objective
response rate (ORR) وL\